Winders, Tonya A.
Wilson, Andrew M.
Fletcher, Monica J.
McGuinness, Anthony
Price, David B.
Funding for this research was provided by:
GSK
GAAPP
Article History
First Online: 17 July 2019
Compliance with Ethical Standards
:
: The PULSAR working group (including the assessment of current severe asthma definitions, travel and accommodation costs, and honoraria for the attendees) was funded by a direct in-kind agency support grant from GSK. Neither the working group members nor authors received any direct compensation related to the development of this manuscript. Editorial support was funded by GSK, through a direct in-kind agency support grant, and Global Allergy Asthma Patient Platform (GAAPP), a not-for-profit network representing over 40 nonprofit patient organizations worldwide (registered in Austria).
: TAW is the elected president (voluntary position) of the Global Allergy Asthma Patient Platform, which is a charity. MJF is an employee of GSK, owns stocks/shares in GSK, and is an honorary research fellow at Asthma UK Centre for Applied Research, The University of Edinburgh. AM is a patient advisor for Asthma UK Centre for Applied Research and receives travel and accommodation expenses from AstraZeneca for a voluntary role in a Patient Partnership Program. DBP is an employee of Observational and Pragmatic Research Institute, Singapore, Singapore and Optimum Patient Care Ltd, Oakington, Cambridge, UK. DBP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrollment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. AMW is an employee at the University of East Anglia and Norfolk and Norwich University Hospital, Norwich, UK. All authors received honoraria and travel costs for attending the PULSAR working group meeting.
: For the survey used, formal consent was not required. Survey responses were provided anonymously, and all patients gave online consent for the results to be shared and included in publications.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.